Aligos Therapeutics, Inc. (ALGS)
NASDAQ: ALGS · Real-Time Price · USD
6.29
-0.14 (-2.18%)
At close: Apr 28, 2026, 4:00 PM EDT
6.29
0.00 (0.00%)
After-hours: Apr 28, 2026, 4:00 PM EDT
Aligos Therapeutics Stock Forecast
Stock Price Forecast
The 3 analysts with 12-month price forecasts for Aligos Therapeutics stock have an average target of 39.33, with a low estimate of 20 and a high estimate of 50. The average target predicts an increase of 525.28% from the current stock price of 6.29.
Analyst Consensus: Strong Buy
* Price targets were last updated on Mar 19, 2026.
Analyst Ratings
The average analyst rating for Aligos Therapeutics stock from 3 stock analysts is "Strong Buy". This means that analysts believe this stock is likely to perform very well in the near future and significantly outperform the market.
Recommendation Trends
| Rating | Nov '25 | Dec '25 | Jan '26 | Feb '26 | Mar '26 | Apr '26 |
|---|---|---|---|---|---|---|
| Strong Buy | 2 | 2 | 3 | 3 | 4 | 3 |
| Buy | 0 | 0 | 0 | 0 | 0 | 0 |
| Hold | 0 | 0 | 0 | 0 | 0 | 0 |
| Sell | 0 | 0 | 0 | 0 | 0 | 0 |
| Strong Sell | 0 | 0 | 0 | 0 | 0 | 0 |
| Total | 2 | 2 | 3 | 3 | 4 | 3 |
Latest Forecasts
| Analyst | Firm | Rating | Rating | Action | Price Target | Upside | Date |
|---|---|---|---|---|---|---|---|
| Jefferies | Jefferies | Strong Buy Initiates $60 → $48 | Strong Buy | Initiates | $60 → $48 | +663.12% | Mar 19, 2026 |
| HC Wainwright & Co. | HC Wainwright & Co. | Strong Buy Reiterates $50 | Strong Buy | Reiterates | $50 | +694.91% | Mar 11, 2026 |
| UBS | UBS | Strong Buy Initiates $20 | Strong Buy | Initiates | $20 | +217.97% | Jan 7, 2026 |
| HC Wainwright & Co. | HC Wainwright & Co. | Strong Buy Reiterates $50 | Strong Buy | Reiterates | $50 | +694.91% | Sep 12, 2025 |
| HC Wainwright & Co. | HC Wainwright & Co. | Strong Buy Initiates $50 | Strong Buy | Initiates | $50 | +694.91% | Aug 18, 2025 |
Financial Forecast
Revenue This Year
2.89M
from 2.19M
Increased by 32.20%
Revenue Next Year
3.03M
from 2.89M
Increased by 4.71%
EPS This Year
-7.29
from -2.45
EPS Next Year
-5.04
from -7.29
Revenue Forecast
| Revenue | 2026 | 2027 | 2028 | 2029 | 2030 | 2031 | 2032 | 2033 |
|---|---|---|---|---|---|---|---|---|
| High | 4.7M | 5.1M | ||||||
| Avg | 2.9M | 3.0M | ||||||
| Low | n/a | n/a |
Revenue Growth
| Revenue Growth | 2026 | 2027 | 2028 | 2029 | 2030 | 2031 | 2032 | 2033 |
|---|---|---|---|---|---|---|---|---|
| High | 116.1% | 78.0% | ||||||
| Avg | 32.2% | 4.7% | ||||||
| Low | - | - |
EPS Forecast
| EPS | 2026 | 2027 | 2028 | 2029 | 2030 | 2031 | 2032 | 2033 |
|---|---|---|---|---|---|---|---|---|
| High | -5.89 | -4.04 | ||||||
| Avg | -7.29 | -5.04 | ||||||
| Low | -8.08 | -7.43 |
EPS Growth
| EPS Growth | 2026 | 2027 | 2028 | 2029 | 2030 | 2031 | 2032 | 2033 |
|---|---|---|---|---|---|---|---|---|
| High | - | - | ||||||
| Avg | - | - | ||||||
| Low | - | - |
Sources: Price targets and analyst ratings provided by Benzinga. Revenue and EPS forecast data provided by Finnhub. The data is sourced from Wall Street analysts. Data disclaimer.